CF Patients on Kalydeco Healthier With Fewer Flares, Study Reports

CF Patients on Kalydeco Healthier With Fewer Flares, Study Reports

297838

CF Patients on Kalydeco Healthier With Fewer Flares, Study Reports

Kalydeco (ivacaftor) safely and effectively improved lung function, growth, and nutrition in children and adults with cystic fibrosis (CF), while reducing rates of pulmonary flares and hospitalizations, according to a real-life study in France. These findings were consistent with those reported in previous clinical trials and real-world studies, confirming the therapy’s benefits both in terms of patients’ health and the use of healthcare resources. The study, “Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness…

You must be logged in to read/download the full post.